0000950170-24-041367.txt : 20240403
0000950170-24-041367.hdr.sgml : 20240403
20240403181400
ACCESSION NUMBER: 0000950170-24-041367
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240401
FILED AS OF DATE: 20240403
DATE AS OF CHANGE: 20240403
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Campbell Bradley L
CENTRAL INDEX KEY: 0001400971
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33497
FILM NUMBER: 24820619
MAIL ADDRESS:
STREET 1: C/O AMICUS THERAPEUTICS, INC.
STREET 2: 1 CEDAR BROOK DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMICUS THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001178879
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 200422823
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3675 MARKET STREET
CITY: PHILADELPHIA
STATE: PA
ZIP: 19104
BUSINESS PHONE: (215) 921-7600
MAIL ADDRESS:
STREET 1: 3675 MARKET STREET
CITY: PHILADELPHIA
STATE: PA
ZIP: 19104
FORMER COMPANY:
FORMER CONFORMED NAME: AMICUS THERAPEUTICS INC
DATE OF NAME CHANGE: 20020729
4
1
ownership.xml
4
X0508
4
2024-04-01
0001178879
AMICUS THERAPEUTICS, INC.
FOLD
0001400971
Campbell Bradley L
47 HULFISH STREET
PRINCETON
NJ
08542
true
true
false
false
President and CEO
true
Common Stock
2024-04-01
4
M
false
7500
8.61
A
894154
D
Common Stock
2024-04-01
4
S
false
7500
11.6661
D
886654
D
Stock Options (right to buy)
8.61
2024-04-01
4
M
false
7500
0.0
D
2025-01-02
Common Stock
7500
60000
D
This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.53 to $11.76 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
All of the options were fully vested and exercisable as of the transaction date.
All transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 23, 2023.
/s/ Christian Formica, Attorney-in-Fact
2024-04-03